VolitionRx enters up to $7.5M at-the-market stock offering agreement with JonesTrading

VOLITIONRX LTD

New 'Capital on Demand' sales agreement with JonesTrading allows sale of up to $7.5M common stock via ATM.
Sales agent commission 3% of gross proceeds; company not obligated to sell any shares.
Replaces prior $25M ATM program with Jefferies, terminated effective April 20, 2025.
Proceeds intended for R&D, product development, clinical studies, commercialization, working capital, and potential acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.